On April 2, 2024, Ian Shakil, the Chief Strategy Officer of Augmedix Inc (AUGX, Financial), sold 97,441 shares of the company. The transaction was reported in a SEC Filing. Following this sale, over the past year, the insider has sold a total of 129,435 shares of Augmedix Inc and has not made any purchases of the stock.
Augmedix Inc is a company that specializes in providing remote medical documentation and live clinical support. The company's technology platform converts natural clinician-patient conversations into medical documentation and provides live support, including referrals, orders, and reminders, so clinicians can focus on what matters most: patient care.
The insider transaction history for Augmedix Inc indicates a trend of more insider sales than buys over the past year. There have been 3 insider buys and 2 insider sells during this period.
On the day of the insider's recent sale, shares of Augmedix Inc were trading at $3.9, resulting in a market cap of $203.732 million.
The stock's price-to-GF-Value ratio stands at 0.81, with a GuruFocus Value of $4.79, suggesting that Augmedix Inc is modestly undervalued according to the GF Value metric.
The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
